Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: A large prospective phase II trial

Endocrine-Related Cancer

Volumn 12, Issue 3, 2005, Pages 657-666

  Berruti, Alfredo ^a   Terzolo, Massimo ^b   Sperone, Paola ^a   Pia, Anna ^c   Della Casa, Silvia ^d   Gross, David J ^e   Carnaghi, Carlo ^f   Casali, Paolo ^g   Porpiglia, Francesco ^h   Mantero, Franco ⁱ   Reimondo, Giuseppe ^b   Angeli, Alberto ^b   Dogliotti, Luigi ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c S CROCE E CARLE HOSPITAL   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h SAN LUIGI GONZAGA HOSPITAL   (Italy)

ⁱ UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; MITOTANE;

ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; FEMALE; GASTROINTESTINAL TOXICITY; HEMOGLOBIN DETERMINATION; HUMAN; LEUKOCYTE COUNT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; THROMBOCYTE COUNT; VOMITING;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MITOTANE; NEOPLASM STAGING; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 26944468635     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01025     Document Type: Article

References (28)

1. Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, Bartlett D, Choyke P, Robey R et al. 2002 A Phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94 2333-2343.
2. Allolio B, Hahner S, Weismann D & Fassnacht M 2004 Management of adrenocortical carcinoma. Clinical Endocrinology 60 273-287.
3. Bates SE, Shieh CY, Mickley LA, Dichek HL, Gazdar A, Loriaux DL & Fojo AT 1991 Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. Journal of Clinical Endocrinology and Metabolism 73 18-29.
4. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G & Schlumberger M 2001 Impact of monitoring plasma 1,1- dichlorodiphenildichloroetane (o.p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92 1385-1392.
5. Berruti A, Terzolo M, Paccotti P, Veglio F, Pia A, Dogliotti L & Angeli A 1992 Favourable response of metastatic adrenocortical carcinoma to etoposide, adriamycin, and cisplatin chemotherapy. Report of two cases. Tumori 78 345-348.
6. Berruti A, Terzolo M, Pia A, Angeli A & Dogliotti L 1998 Mitotane associated with etoposide doxorubicin and cisplatin in the treatment of advanced adrenocortical carcinoma. Cancer 83 2194-2200.
7. Bonacci R, Gigliotti A, Baudin E, Wion-Barbot N, Emy P, Bonnay M, Cailleux AF, Nakib I & Schlumberger M 1998 Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. British Journal of Cancer 78 546-549.
8. Bukowski RM, Wolfe M & Levine HS 1993 Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma. A Southwest Oncology Group Study. Journal of Clinical Oncology 11 161-165.
9. Crucitti F, Bellantone R, Ferrante A, Boscherini M & Crucitti P 1996 The Italian Registry for adrenal cortical carcinoma: analysis of a multi-institutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 119 161-170.
10. Decker RA, Elson P, Hogan TF, Citrin DL, Westring DW, Banerjee TK, Gilchrist KW & Horton J 1991 Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110 1006-1013.
11. Dimopoulos MA, Fernandez JF, Samaan NA, Holoye PY & Vassilopoulou-Sellin R 1992 Paraneoplastic Gushing Syndrome as an adverse prognostic factor in patients who die early with small-cell lung cancer. Cancer 69 66-71.
12. Haak HR, Hermans J & van de Velde CJ 1994 Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. British Journal of Cancer 69 947-951.
13. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF & Proye C 2001 Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World Journal of Surgery 25 891-897.
14. Kasperlik-Zaluska AA 2000 Clinical results of the use of mitotane for adrenocortical carcinoma. Brazilian Journal of Medical and Biological Research 33 1191-1196.
15. Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, Wilander E, Oberg K & Eriksson B 2000 Streptozotocin and o,p'DDD in the treatment of adrenocortical cancer patients: long term survival in its adjucvant use. Annals of Oncology 11 1281-1287.
16. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P et al. 1990 Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. New England Journal of Medicine 322 1195-1201.
17. Miller AB, Hoogstraten B, Staquet M & Winkler A et al. 1981 Reporting results of cancer treatment. Cancer 47 207-214.
18. Pia A, Berruti A, Terzolo M, Paccotti P, Letizia C, Dogliotti L & Angeli A 1995 Feasibility of the association of mitotane with etoposide, adriamycin, and cisplatin combination chemotherapy in advanced adrenocortical cancer patients. Annals of Oncology 6 509-510.
19. Preusser P, Wilke H, Acterrath W, Fink U, Lenaz L, Heincke A, Meyer J & Meyer Buente J 1989 Phase II study with the combination of etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. Journal of Clinical Oncology 171 1310-1317.
20. Ribeiro RC, Michalkiewicz EL, Figueiredo BC, DeLacerda L, Sandrini F, Pianovsky MD, Sampaio G & Sandrini R 2000 Adrenocortical tumors in children. Brazilian Journal of Medical and Biological Research 33 1225-1234.
21. Schlumberger M, Brugieres L, Gicquel C, Travagli JP, Droz JP & Parmentier C 1991 5-fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 67 2997-3000.
22. Schulick RD & Brennan MF 1999 Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Annals of Surgical Oncology 6 719-726.
23. Simon R 1989 Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 10 1-10.
24. Terzolo M, Pia A, Berruti A, Osella G, Ali A, Carbone V, Testa E, Dogliotti L & Angeli A 2000 Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism 85 2234-2238.
25. Van Slooten H & van Oosterom AT 1983 CAP (Cyclophosphamide, Doxorubicin and Cisplatin) regimen in adrenal cortical carcinoma. Cancer Treatment Reports 67 377-379.
26. Villa R, Orlandi L, Berruti A, Dogliotti L & Zaffaroni N 1999 Modulation of cytotoxic drug activity by mitotane and Ionidamine in human adrenocortical carcinoma cells. International Journal of Oncology 14 133-138.
27. Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH & Crawford ED 2000 Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenanocortical carcinoma: a Southwest Oncology Group Study. Cancer 88 1159-1165.
28. Wooten MD & King DK 1993 Adrenocortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72 3145-3155.